UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported) |
August 27, 2015 |
MEDITE CANCER DIAGNOSTICS, INC.
(Exact Name of Registrant as Specified in
Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
333-143570 |
36-4296006 |
(Commission File Number) |
(IRS Employer Identification No.) |
4203 SW 34th St. |
|
Orlando, FL |
32811 |
(Address of Principal Executive Offices) |
(Zip Code) |
(407)
996-9630
(Registrant’s telephone number, including
area code)
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01 Entry
into a Material Definitive Agreement
On August 25, 2015, MEDITE Cancer Diagnostics, Inc., a Delaware
corporation (the "Company") entered into an agreement with its Mexican Distributor, ATDYE, for the delivery of 31 MEDITE
tissue staining machines, with a total retail value of approximately $600,000 to the Company. ATYDE has ordered 13 units of MEDITE’s
Programmable Slide Stainer TST44 and 18 units of MEDITE Continuous Linear Stainer COT20. On August 25, 2015, the Company also delivered
the first 10 units of the new developed manual microtome M380 to our Chinese partner UNIC Medical.
Item 9.01 Financial Statements and
Exhibits.
Exhibit 99.1. Press
Release
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
MEDITE CANCER DIAGNOSTICS, INC. |
|
|
|
|
|
|
Date: August 27, 2015 |
By: |
/s/ Michaela Ott |
|
|
Michaela Ott |
|
|
Chief Executive Officer |
EXHIBIT 99.1
Press Release
MEDITE Cancer Diagnostics, Inc.
Successfully obtained Mexican Tender for 31 Stainers
and First Delivery of new Manual Microtome to China
Orlando, FL., August 27, 2015 -
MEDITE Cancer Diagnostics, Inc., (OTC/QB: MDIT) specializing in the development, manufacturing, and marketing of molecular biomarkers
and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces its Mexican
distributor, ATYDE won a public tender for delivery of 31 MEDITE tissue staining machines with a the total retail value of approximately
$600,000. This is the first major sale to Mexico for MEDITE. Also, MEDITE announces the first delivery of 10 units of MEDITE’s
recently developed manual microtome M380 to the Chinese market through MEDITE’s distributor, UNIC Medical.
MEDITE’s Mexican distributor, ATYDE
has ordered 13 units of MEDITE’s Programmable Slide Stainer TST44 and 18 units of MEDITE Continuous Linear Stainer COT20.
“MEDITE’s tissue stainers are completely manufactured in Germany and provide a high level of automation, high quality
and high throughput in staining human tissue for cancer diagnostics in histology laboratories. We look to expand our business with
MEDITE since they are an experienced supplier which can address our needs for high quality, reliable and cost effective histology
and cytology products,” stated Ms. Silvia Ramirez, Account Manager for ATYDE.
MEDITE also has delivered the first
10 units of the new manual microtome M380 to MEDITE’s Chinese partner UNIC Medical. “We are excited about receiving
the recently developed manual microtones from MEDITE. We expect this instrument to address the histology market needs at many
Chinese medical institutions processing tissue samples for cancer diagnostics on a daily basis. MEDITE’s products which
incorporate German standards of high quality engineered mechanics will enhance the quality of patient care and improve operating
efficiencies at our client’s medical institutions. We believe this product will attract many buyers as it offers superior
mechanical quality at an affordable price”, stated Ben Zheng, President of UNIC Medical. “We believe MEDITE, the only
German company manufacturing histology products in Germany such as the microtome M380, has set a superior standard worldwide incorporating
the ability to cut human tissue sections thinner than 1 micron. The newly developed microtome M380 along with many of our current
and future products address a burgeoning need in China, India and other rapidly growing countries by providing state of the art
health care diagnostics tools for governments and private institutions allowing for the improvement of their citizens’ quality
of life,“ stated Michaela Ott, CEO of MEDITE Cancer Diagnostics, Inc.
As part of a government initiative, MEDITE
along with its distribution partner UNIC Medical is working to standardize the Chinese histology laboratory process using MEDITE
equipment, consumables, immuno-assays, along with the approved UNIC scanning technology for digitalization and computer aided diagnostics
utilizing the latest cloud technology. UNIC Medical is a subsidiary of UNIC Group, a high tech company focused on automated digital
optical quality assurance technology. In 2014, MEDITE successfully received Chinese Food and Drug Administration (“CFDA”)
approval for all MEDITE histology laboratory devices. The CFDA application for the cytology product line currently is in preparation,
and approval is expected in 2015.
About MEDITE Cancer Diagnostics, Inc.
MEDITE Cancer Diagnostics Inc., is a Delaware registered company consisting of wholly-own MEDITE GmbH a Germany-based Company,
with its subsidiaries CytoGlobe GmbH (Cytology Products, Germany), MEDITE GmbH (Distributor, Austria), MEDITE Inc. (Distributor,
Americas) and MEDITE sp. z o.o. (R&D Poland). Since 1978, the MEDITE® group of companies has specialized in the development,
manufacture and distribution of medical laboratory automation equipment and supplies for pathology, histology and cytology. For
these fields, MEDITE offers a complete range of devices and consumables. MEDITE currently sells into 70 countries and is
the market leader in Germany. Through CytoGlobe, a wholly owned subsidiary, MEDITE offers a full range of products for Cytology
labs. Additional information on MEDITE’s products and services can be found at www.medite-group.com. On April 3, 2014, MEDITE
was acquired by CytoCore, Inc. a bio molecular diagnostics company engaged in the design, development, and commercialization of
cost-effective cancer screening systems and Biomarkers to assist in the early detection of cancer. The name of the company changed
from CytoCore, Inc. to MEDITE Cancer Diagnostics, Inc. in December 2014.
Forward Looking Statement
This press release includes forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended, regarding future operating performance, events, trends and plans. All statements other than statements
of historical fact contained herein, including, without limitation, statements regarding our future financial position, business
strategy, budgets, projected revenues and costs, and plans and objectives of management for future operations, are forward-looking
statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,”
“will,” “expects,” “intends,” “plans,” “projects,” “estimates,”
“anticipates,” or “believes” or the negative thereof or any variation thereon or similar terminology or
expressions. We have based these forward-looking statements on our current expectations and projections about future events. These
forward-looking statements are not guarantees and are subject to known and unknown risks, uncertainties and assumptions about us
that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results,
levels of activity, performance or achievements expressed or implied by such forward-looking statements. Important factors that
could cause our actual results to differ from our expectations, include but are not limited to, MEDITE’s ability to maintain
and grow its revenues, as well as those risk factors that apply to our operations as disclosed in Item 1A of our Report on Form
10-K for the year ended December 31, 2014 and other filings with the Securities and Exchange Commission. Readers are cautioned
not to place undue reliance on our forward-looking statements, as they speak only as of the date made. Such statements are not
guarantees of future performance or events and we undertake no obligation to disclose any revision to these forward-looking statements
to reflect events or circumstances occurring after the date hereof.
For more
information please visit: www.medite-group.com
Investor Contact:
Robert McCullough, Jr. CFO
407
996 9630
Medite Cancer Diagnostics (CE) (USOTC:MDIT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medite Cancer Diagnostics (CE) (USOTC:MDIT)
Historical Stock Chart
From Apr 2023 to Apr 2024